Comparative Pharmacology
Head-to-head clinical analysis: CELONTIN versus DEPAKENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELONTIN versus DEPAKENE.
CELONTIN vs DEPAKENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases levels of gamma-aminobutyric acid (GABA) in the central nervous system, possibly by inhibiting GABA transaminase or enhancing GABA release; also reduces calcium influx into neurons, stabilizing neuronal membranes.
Increases GABA concentration in the brain by inhibiting GABA transaminase and blocking voltage-gated sodium channels; also modulates histone deacetylase activity.
300 mg orally three times daily, increased by 300 mg every 3-4 days as tolerated; usual maintenance dose 900-2400 mg/day in divided doses.
Oral: Initial 15 mg/kg/day divided into 1-3 doses, increase by 5-10 mg/kg/day weekly; typical maintenance 30-60 mg/kg/day. Intravenous: Same total daily dose as oral, administered as continuous infusion or divided q6h.
None Documented
None Documented
Terminal elimination half-life: 40-60 hours in adults, 30-45 hours in children; prolonged liver disease or renal impairment may increase half-life.
10-16 hours (monotherapy); 5-9 hours in patients on enzyme-inducing co-medications; prolonged in hepatic impairment (up to 30 hours) or neonates.
Renal: approximately 40-60% as unchanged drug; hepatic metabolism accounts for the remainder, with metabolites excreted renally.
Renal: <3% unchanged; primarily hepatic metabolism via glucuronidation (50%) and beta-oxidation (40%), with metabolites excreted renally. Fecal: negligible.
Category C
Category C
Anticonvulsant
Anticonvulsant